中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经肝动脉化疗栓塞术治疗肝细胞癌合并门静脉癌栓的预后影响因素分析

张成 祁兴顺 柏明 赵艳 王维娟 韩国宏

引用本文:
Citation:

经肝动脉化疗栓塞术治疗肝细胞癌合并门静脉癌栓的预后影响因素分析

DOI: 10.3969/j.issn.1001-5256.2016.01.014
详细信息
  • 中图分类号: R735.7

Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma complicated by portal vein tumor thrombus

  • 摘要:

    目的评估肝细胞癌(HCC)合并门静脉癌栓患者经肝动脉化疗栓塞术(TACE)治疗后的效果及影响预后的因素。方法回顾性分析2006年1月-2010年12月第四军医大学西京医院收治的152例行TACE治疗的HCC合并门静脉癌栓患者的临床资料。观察TACE术后肝衰竭、上消化道大出血、栓塞后综合征等发生情况,分析生存期资料与影响预后的因素。Kaplan-Meier法计算累积生存率,采用Log-Rank法进行单因素分析,Cox比例风险模型进行多因素分析。结果患者中位生存时间为5.0(95%可信区间:4.45.6)个月,6、12、18个月的累积生存率分别为37%、18%和9%。单因素分析显示肿瘤大小、肿瘤类型、肝两叶累及、远处转移和Child-Pugh分级是HCC合并门静脉癌栓患者行TACE治疗预后的影响因素(χ2值分别为5.108、11.542、6.036、12.319、22.574,P值均<0.05);多因素分析显示肿瘤大小、肿瘤类型、远处转移和Child-Pugh分级是影响患者预后的独立危险因素(Wald值分别为11.243、5.021、7.651、25.876,P...

     

  • [1]CHUNG JW,PARK JH,HAN JK,et al.Hepatocellular carcinoma and portal vein invasion:results of treatment with transcatheter oily chemoembolization[J].AJR Am J Roentgenol,1995,165(2):315-321.
    [2]IZUMI R,SHIMIZU K,LI T,et al.Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection[J].Gastroenterology,1994,106(3):720-727.
    [3]KUO YH,LU SN,CHEN CL,et al.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J].Eur J Cancer,2010,46(4):744-751.
    [4]LAU WY,LAI EC,YU SC.Management of portal vein tumor thrombus[M]//LAU WY,Eds.Hepatocellular carcinoma.Singapore:World Scientific Publishing,2008:739-760.
    [5]LLOVET JM,REAL MI,MONTAA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.
    [6]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.
    [7]YAMADA R,SATO M,KAWABATA M,et al.Hepatic artery embolization in 120 patients with unresectable hepatoma[J].Radiology,1983,148(2):397-401.
    [8]KIM KM,KIM JH,PARK IS,et al.Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion[J].J Gastroenterol Hepatol,2009,24(5):806-814.
    [9]LUO J,GUO RP,LAI EC,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study[J].Ann Surg Oncol,2011,18(2):413-420.
    [10]CHUNG GE,LEE JH,KIM HY,et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J].Radiology,2011,258(2):627-634.
    [11]BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.
    [12]SONG B,MIN P,OUDKERK M,et al.Cavernous transformation of the portal vein secondary to tumor thrombosis of hepatocellular carcinoma:spiral CT visualization of the collateral vessels[J].Abdom Imaging,2000,25(4):385-393.
    [13]PENTECOST MJ,DANIELS JR,TEITELBAUM GP,et al.Hepatic chemoembolization:safety with portal vein thrombosis[J].J Vasc Interv Radiol,1993,4(3):347-351.
  • 加载中
计量
  • 文章访问数:  2479
  • HTML全文浏览量:  14
  • PDF下载量:  409
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-10-21
  • 出版日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回